Stocks and Investing Stocks and Investing
Mon, October 3, 2022
Sun, October 2, 2022
Fri, September 30, 2022
Thu, September 29, 2022
Wed, September 28, 2022
Tue, September 27, 2022

Vikram Purohit Maintained (ARQT) at Buy with Increased Target to $46 on, Sep 27th, 2022


Published on 2024-10-27 23:07:18 - WOPRAI, Vikram Purohit
  Print publication without navigation


Vikram Purohit of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Increased Target from $45 to $46 on, Sep 27th, 2022.

Vikram has made no other calls on ARQT in the last 4 months.



There are 4 other peers that have a rating on ARQT. Out of the 4 peers that are also analyzing ARQT, 0 agree with Vikram's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Vikram


  • Sean Kim of "JonesTrading" Initiated at Strong Buy and Held Target at $54 on, Thursday, September 22nd, 2022
  • Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $46 on, Wednesday, September 7th, 2022
  • Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, August 2nd, 2022
  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $39 on, Tuesday, June 7th, 2022